Latest news with #Compugen
Yahoo
3 days ago
- Business
- Yahoo
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
HOLON, Israel, June 12, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen's scientific capabilities in understanding complex cancer biology. Poster details: Conference: 2025 Annual Congress of the European Association for Cancer Research, June 16-19 Lisbon, PortugalPoster number: EACR25-3113Title: Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypesPresenting author: Amir Toporik, Computational Discovery, CompugenDate of presentation: June 18, 2025 Conference: International Society for Computational Biology and European Conference on Computational Biology- Annual International Conference on Intelligent Systems for Molecular Biology, July 20-24, 2025, Liverpool, UKPoster number: 947Title: Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanismsPresenting author: Itamar Borukhov, Ph.D., Computational Discovery, Compugen Posters will be available in the publications section of Compugen's website, following presentation. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Yvonne Naughton, of Investor Relations and Corporate CommunicationsEmail: ir@ +1 (628) 241-0071 View original content: SOURCE Compugen Ltd.
Yahoo
25-05-2025
- Business
- Yahoo
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts
One thing we could say about the analysts on Compugen Ltd. (NASDAQ:CGEN) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon. Shares are up 4.3% to US$1.45 in the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity. Our free stock report includes 2 warning signs investors should be aware of before investing in Compugen. Read for free now. Following the downgrade, the consensus from four analysts covering Compugen is for revenues of US$14m in 2025, implying a painful 49% decline in sales compared to the last 12 months. Losses are supposed to balloon 82% to US$0.28 per share. However, before this estimates update, the consensus had been expecting revenues of US$31m and US$0.12 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts. View our latest analysis for Compugen Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 59% by the end of 2025. This indicates a significant reduction from annual growth of 63% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. It's pretty clear that Compugen's revenues are expected to perform substantially worse than the wider industry. The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Compugen. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We wouldn't be surprised to find shareholders feeling a bit shell-shocked, after these downgrades. It looks like analysts have become a lot more bearish on Compugen, and their negativity could be grounds for caution. Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Compugen going out to 2027, and you can see them free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
25-05-2025
- Business
- Yahoo
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts
One thing we could say about the analysts on Compugen Ltd. (NASDAQ:CGEN) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon. Shares are up 4.3% to US$1.45 in the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity. Our free stock report includes 2 warning signs investors should be aware of before investing in Compugen. Read for free now. Following the downgrade, the consensus from four analysts covering Compugen is for revenues of US$14m in 2025, implying a painful 49% decline in sales compared to the last 12 months. Losses are supposed to balloon 82% to US$0.28 per share. However, before this estimates update, the consensus had been expecting revenues of US$31m and US$0.12 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts. View our latest analysis for Compugen Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 59% by the end of 2025. This indicates a significant reduction from annual growth of 63% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. It's pretty clear that Compugen's revenues are expected to perform substantially worse than the wider industry. The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Compugen. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We wouldn't be surprised to find shareholders feeling a bit shell-shocked, after these downgrades. It looks like analysts have become a lot more bearish on Compugen, and their negativity could be grounds for caution. Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Compugen going out to 2027, and you can see them free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
20-05-2025
- Business
- Yahoo
Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
Cash Balance: Approximately $103.7 million as of March 31, 2025. Revenue: Approximately $2.3 million for Q1 2025, compared to $2.6 million in Q1 2024. R&D Expenses: Approximately $5.8 million for Q1 2025, compared to $6.4 million in Q1 2024. G&A Expenses: Approximately $2.4 million for both Q1 2025 and Q1 2024. Net Loss: Approximately $7.2 million or $0.08 per share for Q1 2025, compared to $7.3 million or $0.08 per share in Q1 2024. Cash Runway: Expected to fund operating plans into 2027. Warning! GuruFocus has detected 3 Warning Signs with CGEN. Release Date: May 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) has initiated a sub-trial for their anti-PVRIG antibody COM701 in ovarian cancer, targeting an unmet medical need. The company has a strong cash position with a runway extending into 2027, supporting their clinical and research activities. Compugen Ltd (NASDAQ:CGEN) is advancing its early-stage and clinical immuno-oncology pipeline, focusing on innovative therapies. Partnership with AstraZeneca is progressing, with multiple Phase 3 trials initiated, potentially leading to significant revenue opportunities. The company is exploring novel mechanisms of action in their early-stage pipeline, aiming to enhance anticancer immunity. Revenues for the first quarter of 2025 decreased compared to the same period in 2024. The company reported a net loss of approximately $7.2 million for the first quarter of 2025. There is uncertainty in the TIGIT landscape, with previous Phase 3 failures impacting market sentiment. The success of Compugen Ltd (NASDAQ:CGEN)'s TIGIT program is contingent on positive outcomes from upcoming Phase 3 trials. The competitive landscape in ovarian cancer is evolving, with new therapies potentially impacting Compugen Ltd (NASDAQ:CGEN)'s strategy. Q: Merck's KEYNOTE-B96 Phase 3 study in pembrolizumab for platinum-resistant ovarian cancer was successful. How might this impact your strategy in ovarian cancer? A: Michelle Mahler, Chief Medical Officer: The study is in a different setting, but it shows benefit from adding an immune checkpoint inhibitor. If our study demonstrates activity, it could open opportunities to combine COM701 in broader populations. Q: What is your interpretation of Roche's SKYCRAPER-01 data, and how does it affect your confidence in TIGIT antagonism? A: Eran Ophir, Vice President - Research, Drug Discovery: Despite the failure, we see numerical activity in TIGIT trials. The Fc active format may have contributed to high discontinuation rates. We believe Fc inactive antibodies, like ours, may offer safety and efficacy advantages. Q: Do you plan to collect data on tumor microenvironment features in the COM701 study? What PFS benefit would be clinically meaningful in the maintenance setting? A: Michelle Mahler, Chief Medical Officer: We will collect data on the tumor microenvironment but won't disclose details. An improvement of around three months in progression-free survival would be clinically meaningful. Q: Have you observed activity of COM701 in PD-L1 positive patients, and what are your thoughts on PD-1 VEGF bispecifics? A: Michelle Mahler, Chief Medical Officer: We see activity in both PD-L1 positive and negative patients. Eran Ophir, Vice President - Research, Drug Discovery: VEGF increases T cell infiltration, complementing PVRIG biology. Fc inactive TIGIT may be preferable for combinations due to safety concerns. Q: What are your thoughts on the potential synergy between TIGIT, PD-1, and VEGF inhibitors? A: Eran Ophir, Vice President - Research, Drug Discovery: VEGF can enhance T cell infiltration, aligning with PVRIG biology. While we haven't published data, combining with Fc inactive TIGIT could be advantageous due to safety profiles. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
19-05-2025
- Business
- Washington Post
Compugen: Q1 Earnings Snapshot
HOLON, Israel — HOLON, Israel — Compugen Ltd. (CGEN) on Monday reported a loss of $7.2 million in its first quarter. On a per-share basis, the Holon, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2.3 million in the period. The company's shares closed at $1.37. A year ago, they were trading at $2.11.
